在中国男性健康的隐秘角落里,一场持续二十余年的市场暗战,正迎来新的变局。 曾经,一粒蓝色小药片定义了一个时代。作为全球首款口服ED(勃起功能障碍)治疗药物,辉瑞的万艾可于1998年横空出世,2000年进入中国,从此“伟哥”一词成了这个品类的代名词。紧随其后,礼来的希爱力以“36小时长效”的差异化定位入局,与万艾可、拜耳艾力达形成外资三足鼎立的格局。直到2014年,白云山的金戈以国产首仿身份登场,...
Source Link在中国男性健康的隐秘角落里,一场持续二十余年的市场暗战,正迎来新的变局。 曾经,一粒蓝色小药片定义了一个时代。作为全球首款口服ED(勃起功能障碍)治疗药物,辉瑞的万艾可于1998年横空出世,2000年进入中国,从此“伟哥”一词成了这个品类的代名词。紧随其后,礼来的希爱力以“36小时长效”的差异化定位入局,与万艾可、拜耳艾力达形成外资三足鼎立的格局。直到2014年,白云山的金戈以国产首仿身份登场,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.